(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer (TEST)
(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer (TEST)
An interactive patient case video series from breast cancer specialists
An interactive patient case video series from breast cancer specialists
Prof Valentina Guarneri
In this first interactive patient case video from BREAST CANCER CONNECT expert Dr Elisa Agostinetto, you will explore the complexities of a patient facing ER+/HER2- de novo metastatic breast cancer.
As you journey through the entire diagnostic and treatment process, you'll interact and engage with valuable information, challenging questions and clickable resources along the way.
Video 2 Coming Soon: Prof. Valentina Guarneri presents a patient with ER+/HER2- metastatic breast cancer in a second interactive patient case video coming soon.
![](https://test.cor2ed.com/wp-content/uploads/2023/03/Valentina-Guarneri_2.jpg)
Prof Valentina Guarneri
Medical Oncology
University of Padova
Italy
Valentina Guarneri, MD, PhD, is Full Professor of Oncology at the University of Padua, Head of the Division of Oncology 2 at the Istituto Oncologico Veneto, and head of the Specialization School in medical Oncology at the University of Padova. She completed her fellowship in Oncology in 2003, and she obtained her PhD Degree in Clinical and Experimental Oncology in 2007. In 2005 she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia, where she also chaired the Breast Unit. In 2005, she also completed a 6-month-research experience at the Department of Breast Medical Oncology, UT. MD Anderson Cancer Center, Houston, Texas, where in 2009 she was Visiting Assistant Professor. In 2014 she was appointed Associate Professor of Oncology at the University of Padua. Prof Guarneri’s research interest is mainly focused on clinical and translational research for breast cancer patients. She has published more than 200 papers in peer-reviewed journals.
Prof Valentina Guarneri has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
ER+HER2 - De Novo Metastatic Breast Cancer
Interactive patient case |
28 min
|
Sep 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Clinical Takeaways
-
Assessing tumour characteristics, including prevalent mutations like ESR1 and PIK3CA, can significantly influence and guide treatment choices in patients with ER+/HER2- metastatic breast cancer
-
Liquid biopsy, specifically blood-based ctDNA analysis, is the preferred method for detecting ESR1 mutations due to its heightened sensitivity and the avoidance of repeat biopsies at metastatic sites
-
Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2- metastatic breast cancer harbouring an ESR1 mutation
-
Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice
This educational programme is supported by an Independent Medical Education Grant from (TEST) Menarini Stemline Oncology